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Smad proteins are the major signal transducers for the Transforming Growth Factor superfamily of cytokines and their serine/threonine kinase
receptors. Smads mediate the signal from the membrane into the nucleus. Bone Morphogenetic Protein-4 stimulates phosphorylation of Smad1,
which interacts with Smad4. This complex translocates into the nucleus and regulates transcription of target genes. Here, we report our
development of cellular fluorescence biosensors for direct visualization of Smad signaling in live mammalian cells. Fluorescence resonance
energy transfer between cyan and yellow fluorescent proteins fused to the Smad1 and Smad4 proteins was used to unravel the temporal aspects of
BMP/Smad signaling. A rate-limiting delay of 2–5 min occurred between BMP activation and Smad1 activity. A similar delay was observed in the
Smad1/Smad4 complexation. Further experimentation indicated that the delay is dependent on the MH1 domain and linker of Smad1. These
results give new insights into the dynamics of the BMP receptor –Smad1/4 signaling process and provide a new tool for studying Smads.
© 2007 Elsevier B.V. All rights reserved.Keywords: BMP; Smad; GFP; FRET; Biosensor1. Introduction
Bone morphogenetic proteins (BMPs) are members of the
Transforming Growth Factor (TGF-β) superfamily of cytokines
[1,2]. Smad proteins are intracellular mediators of the TGF-β
family of cytokines and receptors, which transduce the signal
from the cell surface into the nucleus and expressed in most, if
not all, cell types. BMP-4 binds to the high-affinity bone
morphogenetic receptor type 1 (BRI) [3] in preformed hetero-
oligomeric complexes with bone morphogenetic receptor type 2
(BRII) [4] to transfer signals into the cell via Smad proteins
[5,6]. By mediating these cytokine responses, Smad proteins
modulate a variety of important biological processes such as
control of cell growth, differentiation, adhesion, and migration
as well as inhibition of proliferation apoptosis and immune
responses [7]. There are three categories of Smads: receptor-
regulated Smads (R-Smads),which formcomplexeswith common-
partner Smad (Co-Smad), and the third class, inhibitory Smads⁎ Corresponding author. Tel.: +49 931 201 48717; fax: +49 931 201 48702.
E-mail address: gregory.harms@virchow.uni-wuerzburg.de (G.S. Harms).
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doi:10.1016/j.bbamcr.2007.09.007(I-Smads) which negatively regulate signaling by the R-Smads
and Co-Smads [7,8]. All Smad proteins contain two structurally
conserved domains. The N-terminal MH1 domain is responsible
for binding to DNA, transcription factors, and also to the
cytoskeletal scaffold [9]. The C-terminal MH2 domain is
responsible for phosphorylation and complex formation between
Smad proteins and for interaction with type I receptors,
transcriptional activation, and degradation by ubiquitination [9–
14].
R-Smads such as Smad1 mediate BMP-4 signaling events.
Upon BMP-4 stimulation, BRII initiates the kinase activity of
BRI leading to the phosphorylation of R-Smad (reviewed in
[15–18]). R-Smads have the structurally important L3 loop in
the MH2 domain which interacts with the type I receptor. Upon
this interaction, the type I receptor kinases directly phosphor-
ylate two distal serines in the C-terminus within the SSXS motif
[19,20]. The current model suggests that two mechanisms con-
trol the specific phosphorylation of the R-Smads by the receptor
kinase complexes. First, a loop structure in the receptor kinase
domain, referred to as the L45 loop, specifically interacts with
the L3 loop of an R-Smad protein [21–24]. Second, a receptor-
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TGF-β/activin pathway, can recruit specific R-Smad proteins
to receptor kinases for phosphorylation [25]. However, the
interplay between receptor activation, the Smad conformation
change upon phosphorylation, and specific Smad binding pro-
teins is not clear.
The phosphorylated Smad1 dissociates from the type I
receptor, presumably due to a conformational change [26], and
forms a complex with the Co-Smad, Smad4. Smad4 does not
have the C-terminal SSXS phosphorylation motif and, thus, is
not phosphorylated by the receptor. Smad4 forms a complex
with activated Smad1 [10,11,27] that translocates to and
accumulates in the nucleus where it is involved in transcriptional
regulation [5,27–29]. Smad proteins in the resting state realize
passive nucleo-cytoplasmic shuttling [30], which is controlled
by two opposing signals: the nuclear localization signal (NLS)
and the nuclear export signal (NES). The regulation of this
shuttling activity constitutes a critical cellular mechanism to
modulate the activities of transcription factors [31–34].
During the signaling processes, Smad proteins can also
interfere with other signaling pathways that can change the
kinetics of Smad phosphorylation, complex formation, and the
dynamics of nuclear translocation [9]. Previously the basic
functions and rates of activation of Smad proteins were shown
and investigated by means of standard biochemical techniques.
Fluorescence microscopy techniques have led to an improved
understanding of these processes. For example, the shuttling of
the Smad4 was determined to be originally due to its basal level
presence in both the cytoplasm and nucleus, which upon either
stimulation [5,17,30,35–37] or by blocking the pore specific for
its NES [37,38] caused nuclear accumulation. Direct evidence of
the shuttling and the shuttling kinetics were determined by
simple time-lapse fluorescence microscopy of translocation and
by combined Fluorescence Loss In Photobleaching (FLIP) and
Fluorescence Recovery After Photobleaching (FRAP) experi-
ments. In these experiments, fluorescence labeled Smads were
first observed to enter the nucleus upon stimulation and were
then photobleached in the area of the nucleus to measure the
diffusion rates in the nucleus and cytoplasm and ratios between
them during stimulation [39,40]. At present, the information
from dynamic optical microscopic techniques indicates that
Smad proteins are more mobile than as indicated from
biochemical techniques. For example, it is not clear why
activation and complexation of R-Smads is relatively slow [7]
when they are apparently freely mobile in the cytoplasm [39].
The studies also indicate that the shuttling is reduced after Smads
form complexes, Smads have their NES motif blocked after
phosphorylation, and phosphorylated pools of Smads do not
exist in the cytoplasm [39]. In these experiments and results,
only fluorescence measurements were performed to indirectly
indicate the detailed events up to Smad signaling, including the
dynamics of phosphorylation and complex formation. Up to
now, the direct imaging analogies to Western blot analyses of
Smad phosphorylation and to immunoprecipitations of Smad
complexes are lacking. Direct imaging could provide the
evidence to find the rate-limiting steps in the process of
phosphorylation and complex formation. In this work we createdfluorescent biosensors of Smad1 and Smad4 proteins.With these
biosensors we observed and monitored the activation of Smad1,
the role of the Smad1 MH1 domain in this activation, and
Smad1/Smad4 complex formation upon BMP-4 stimulation
with detailed and unprecedented time resolution by Fluores-
cence Resonance Energy Transfer (FRET) microscopy.
2. Materials and methods
2.1. Plasmids, reagents and cells
HA-tagged BMP receptors type 1b and 2 were cloned in pcDNA3. BRIb was
used as a best partner of BRII for Smad activation [6]. The DNA fragments
coding fluorescent proteins (CFP and YFP) were PCR amplified from pEYFP
and pECFP (Clontech), respectively and inserted in-frame to the C- or N-
terminus or at the stated positionwithin of the DNA sequences coding for the full-
length Smad protein or only part of Smad1 or Smad4. All fusion constructs were
ligated into the pcDNA3 expression vector (Invitrogen) for transient expression
in mammalian cells. HeLa, HEK 293, COS-1 and MDA-MB468 cell lines were
grown in DMEM/10% FCS and were transiently transfected with FuGENE 6
(Roche Molecular Biochemicals), Effectene, or Superfect (Qiagen) transfection
reagents.
2.2. Western blots
COS-1 cells were transiently transfected with Smad fusion protein and BMP
receptor expression plasmids in a 6-well plate. Twenty-four hours after
transfection, cells were starved in DMEM supplemented with 0.5% fetal calf
serum for 6 h. After incubation with 20 nM of BMP-4 for 5, 15, 30, or 60 min
cells were harvested and lysed in lysis buffer (Cell Signaling Technology). The
lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis using 8 or 12% gels. After electrophoreses, electrotransfer (PEQLAB
Biotechnologie) and blocking (10 mM Tris, pH 7.9, 150 mMNaCl, 0.1% Tween
20, and 5% dry milk; 20 °C, 1 h), the blot was incubated with monoclonal rabbit
antibodies against Phospho-Smad1 (Ser463/465), with anti-Smad1 (Cell
Signaling Technology) or anti-GFP polyclonal antibodies (Abcam) for 20 h at
4 °C. Amounts of protein were also determined with a monoclonal rabbit
antibody against β-actin (Cell Signaling Technology). Detection of adsorbed
antibodies was performed by enhanced chemiluminescence (LumiGLO, Super-
Signal WestPico, Upstate), using an HRP-conjugated secondary anti-rabbit
polyclonal IgG antibody (Upstate) in blocking buffer.
2.3. Luciferase assays
Twenty-four hours before transfection, MDA-MB468 cells were seeded in
triplicate at 2×105 cells per well in a 6-well plate. 0.2 μg each of pSBE-Luciferase
construct (from C. H. Heldin, Ludwig Institute for Cancer Research, Uppsala,
Sweden), 0.05 μg of BMP receptors constructs, and 0.4 μg of indicated fusion
Smad1/Smad4 vectors were co-transfected per well. Thirty-six hours after
transfection, cells were starved in DMEM (0.5% FCS) for 10 h and then incubated
in DMEM (0.5% FCS) with 20 nM BMP-4 for 8 h. To control protein expression
levels and normalize luciferase activity, all samples were transfected with a
Renilla Luciferase coding vector (0.1 μg each). The cells were subsequently
lysed with reporter lysis buffer, and luciferase activity was determined with a
Dual-Luciferase assay kit (Promega) on a FLUOstar (BMG Labtech)
luminometer. Each experiment was repeated at least three times.
2.4. Confocal microscopy
HeLa or COS-1 cells were grown to 50% confluence on 26-mm glass cover
slips, transiently transfected, and incubated in complete DMEM medium for
24 h. After this, cells were incubated for 2 to 5 h with DMEM containing 0.5%
FCS. Cells were analyzed before or after treatment with 20 nM BMP-4 or 20 nM
leptomycin B (LMB). All live cell imaging was performed at 37 °C. The
fluorescence images were recorded on either a modified confocal microscope
(LSM-410, Carl Zeiss and LSMTech) with a 100× NA 1.3 objective (Carl Zeiss)
Fig. 1. Construction of Smad1 FRET biosensor. (A) The Smad1YC fusion
protein was constructed by inserting YFP between the MH1 and MH2 domains
of human Smad1. CFP was attached with specific short linker sequence (L) to
the C-terminus. (B) COS1 cells transfected with the Smad1YC expression
plasmid were stimulated with BMP-4. Cells were harvested at the indicated
times after BMP-4 stimulation and analyzed by Western blot for the presence of
phosphorylated Smad1 (pSmad1). The pSmad1 antibody recognizes both
endogenous pSmad1 and pSmad1YC. Total Smad1YC and β actin are shown as
controls. The identity of the 110-kDa protein as Smad1YC was verified using an
anti-fluorescent protein (αFP) antibody.
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fluorescence emission resulted from excitation with 458 (for CFP) and 514 (for
YFP) nm laser lines from an argon ion laser (Coherent Inova, I-308) from the
modified Zeiss LSM-410 or Lasos (DMI 600B, Germany) with the Leica SP5
LSM confocal with internal spectral parameter settings of 458 for CFP and
514 nm for YFP. The fluorescence was detected with either optical filter sets
from the microscope manufacturer using a 475–495 band pass filter for CFP and
a 530585 band pass filter for YFP or with SP5 a 490–500 nm spectral band
width setting for CFP and a 520–590 nm spectral band width setting for YFP.
2.5. FRET microscopy measurements
In this study, a fluorescence microscope was used to perform FRET
measurements [41–43]. We quantified the FRET signal by calculating excess
acceptor emission using FRET ratios from defined regions of interest in, for
example, the cytoplasm. The setup for fluorescence resonance energy transfer
between the cyan and yellow fluorescent proteins comprises an inverted
microscope (Axiovert 200, Carl Zeiss) equipped with a high numerical aperture
objective (Plan Apochromat 100×, 1.4 NA, Carl Zeiss). Samples were excited
with wide-field light from a computer-driven monochromator Xenon lamp
source (Polychrome IV, Till Photonics) at 436±5 nm (CFP) and 480±5 nm
(YFP) that was connected to the microscope with an optical light guide and
optical focusing system (Till Photonics) with the excitation light reflected by a
dichroic beamsplitter (for CFP and FRET measurements, DCLP 460 or for YFP
measurements, DCLP 490, Chroma) into the microscope objective. The
fluorescence CFP and YFP signals were detected in the emission light train of
the microscope by avalanche photodiodes (Till Photonics) separated by a
dichroic beam splitter at 505 nm (DCLP 505, Chroma) and with bandpass
filters in front of each of the detectors, one at 480±20 nm (HQ480/40, Chroma)
for CFP emission and the other at 535±15 nm (HQ535/30, Chroma,) for YFP
emission, and were digitalized using an AD converter (Digidata1322A, Axon
Instruments) and stored on a personal computer using Clampex 8.1 software
(Axon Instruments) that also synchronized the excitation wavelength with the
data acquisition. In a few cases fluorescence images and recordings were made
by detection from a CCD camera (Coolsnap HQ, Photometrics) with the image
on the CCD camera split spectrally in half and re-imaged on the CCD with a
relay system with a dichroic beam splitter at 505 nm and two filtered split
images bandpass filtered again with the a 480±20 nm for CFP emission and the
other at 535±15 nm for YFP emission (Dual View, Optical Insights). FRET
(including the individual CFP and YFP) signals and images were acquired every
0.1 or 1 s.
FRET is calculated as the ratio of the corrected YFP and CFP emission
intensities at 535±15 nm (IYFP) and 480±20 nm (ICFP(436) ): IYFP/ICFP(436)
upon excitation of CFP at 436±5 nm (beam splitter DCLP 460 nm). The YFP
(acceptor) direct excitation factor was determined with YFP transfected cells
only. The YFP fluorescence was recorded first with 436±5 nm excitation
(FY,436). Next the YFP emission was recorded with 480 nm excitation (FY,480).
The direct excitation crosstalk was calculated by FY,436/FY,480 and was equal to
0.06±0.01. The YFP only cells did not show any emission intensity in the CFP
emission channel with 436±5 nm excitation. The bleed-through or spillover
crosstalk of CFP (donor) into the 535-nm channel was determined first from
cells expressing CFP with 436±5 nm excitation (and also of pure recombinant
CFP) only showed that the 535 nm channel had 80% of the intensity of the
480 nm channel. The FRET ratio calculation was performed in the following
steps to ensure correct subtractions of signals for FRET [44]: (1) we identify and
subtract the spillover of the CFP in the YFP channel to determine the pure YFP
component due to FRET and direct excitation: YFPsum= IYFP(436 nm)− ICFP
(436 nm)×0.8, 2) we identify and subtract the direct excitation component to
determine the YFP signal due to FRET: YFPFRET (or IYFP)=YFPsum−0.06×
YFP(480 nm), and 3) the FRET ratio was then calculated by the formula:
FRETratio= IYFP/ICFP(436 nm).
FRET data were acquired for a long time periods before ligand addition to
make sure that both the cyan site and yellow fluorescent protein signals were
stable and were not photobleaching. Otherwise, the measurements were
discontinued and not included in these results.
To study agonist-induced changes in FRET, cells were placed in FRET-
buffer or in DMEM (0.5% FCS) and BMP-4 (20 mM) was applied. As a
negative control on the cell the FRET-buffer or DMEM (0.5% FCS) was appliedto show that the FRETchange was induced by BMP-4 addition but not by buffer
or media. The imaging data were analyzed with Origin (Microcal) software.
ImageJ and MetaMorph 5.0 (Universal Imaging) were also used in some cases.
All live cell imaging was performed at 37 °C.
We proved FRET by photobleaching the acceptor and then observed the
donor dequenching (donor signal increase) and also by FLIM FRET imaging
(see below). The calculation of relative CFP:YFP concentrations for the
intermolecular FRET were corrected by dividing by the brightness of the indi-
vidual, initial CFP (ICFP(436)) and YFP (IYFP,corr) intensities:
ICFP(436)/(tCFP εCFP,436 φCFP) and IYFP, corr/(tYFP εYFP,436 φYFP) where tCFP
and tYFP are the optical transmissions for CFP and YFP in the respective CFP
(0.35) and YFP (0.60) detection channels, εCFP,436 and εYFP,436 are the molar
extinction coefficients of CFP (28,000 M−1 cm−1) and YFP (7,000 M−1 cm−1)
at 436±5 nm excitation, respectively, and φCFP and φYFP are the fluorescence
quantum yields of CFP (0.36) and YFP (0.76) [45,46].
2.6. Fluorescence Lifetime Imaging (FLIM) and FLIM FRET
determinations
HeLa or COS-1 cells were grown to 50% confluence on 26-mm glass cover
slips, transiently transfected with the CFP-Smad1 and YFP-L-Smad-4 plasmids
(as individuals for control and co-transfected for the FRET experiments), and
incubated in full DMEMmedium for 24 h. After this, cells were incubated for 2 to
5 h with DMEM without serum. Cells were analyzed before and after treatment
with 20 nM BMP-4 (Sigma) every 15 min after addition of BMP-4 up to 45 min.
All imaging experiments were performed on a Leica SP5 confocal laser scanning
microscope (Leica) using a DMI 6000 inverted microscope stand with a HCX PL
APO lamda blue 63x/1.4 OIL UV objective, equipped with a “multi-function
port” with a mechanically controlled beamsplitter that could be automatically
placed in the excitation and imaging beam pathway for reflection of the laser
excitation light and transmission of the fluorescence emission light and also with
two built-in spectrally selective photon counting detectors (set at 460–500 nm for
CFP and 520–590 nm for YFP, respectively for each channel) with a detector
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FLIM excitation source was a Ti:Sapphire femtosecond pulsed laser (Maitai HP,
Spectra-Physics). The laser was tuned to provide a wavelength of 860 nm. A
second harmonic generation (SHG) crystal (LBO-Crystal for SHG wavelength:
800–1100 nm, LINOS Photonics) was used to frequency double the wavelength
from 860 nm to 430 nm which efficiently excites CFP and causes minimal
excitation of YFP. All remaining 860 nm light was filtered out by a 510 dcxrt
dichroic (Chroma) which reflected the 430-nm pulsed excitation beam into the
“multifunction port” and, thus, the Leica SP5 scanning and imaging system. The
430-nm laser power for all experimentswasmeasured at the objective to be 5μW.
Live cells on glass coverslips (26mm)were imaged using a homebuilt incubation
chamber kept at 37 °C via an objective heater (PeCon).Fig. 2. Intramolecular FRET kinetics measurement. (A) Measurement and (B) comp
points) represented by the ratio FYFP/FCFP from (C), the individual FYFP and FCF
Smad1YC and BMP receptors. Stimulation with BMP-4 began with nearly no resp
exponential time constant of about 300 s was observed with corresponding decreas
computerized analysis of FRET (represented by the ratio FYFP/FCFP) in single COS-1
with BMP-4 in a minority of cases began with a slow decrease in the FRETchannel of
decrease in FRET (left panel).The FLIM measurements were carried out by time-correlated single photon
counting (TCSPC) recording and used the ‘reversed start-stop’ approach, with
accurate laser synchronization from a Becker & Hickl SPC-830 card (Becker &
Hickl) together with a PHD-400-N reference photodiode recording the 80-MHz
pulse frequency of the frequency excitation light. The Leica SP5 software
recorded images and split the amplified signal between the Leica imaging
software (LASAF, Leica) and the SPC-830 TPSPC card controlled by the SPC-
830 software on a separate computer with the imaging synchronized via the
external output of the frame, line, and pixel clock from the Leica SP5 into the
SPC-830.
FLIM (TCSPC) recordings were acquired routinely for between 120 s and
150 s. The mean photon counts were between 104 and 105 counts per second touterized analysis of FRET (black line of fit in the gray calculated measurement
P corrected measurements in single COS-1 cell transiently co-transfected with
onse in the FRET ratio until after about 300 s, when a FRET change with an
e in the YFP channel and increase in the CFP channel. (D) Measurement and
cells transiently transfected with Smad1(SA)YC and BMP receptors. Stimulation
about 880 s (right panel) or in the majority of cases with no significant change or
Fig. 3. Construction of Smad1 MH2 domain-based FRET biosensor. (A) The
YSmad1C fusion protein was constructed by flanking the human Smad1 MH2
domain with YFP and CFP. CFP was attached with the specific short linker
sequence (L) to the C-terminus. The construct does not contain the MH1 domain
and the MH1 linker. (B) COS1 cells transfected with the YSmad1C expression
plasmid were stimulated with BMP-4. Cells were harvested at the indicated
times after BMP-4 stimulation and analyzed by Western blot for the presence of
phosphorylated Smad1 (pSmad1). Total YSmad1C was detected using an anti-
fluorescent protein (αFP) antibody.
Fig. 4. Intramolecular FRET kinetics measurement. (A) Measurement and
(B) computerized analysis of FRET (black line of fit in the gray calculated
measurement points) represented by the ratio FYFP/FCFP from panel C, the
individual FYFP and FCFP corrected measurements in single COS-1 cell
transiently transfected with YSmad1C and BMP receptors. Stimulation of the
YSmad1C transfected cells with BMP-4 leads to a rapid decrease of FRET in
about 300 s and a slow recovery phase of about 600 s with corresponding and
decreases in YFP channel and increases in CFP. (D) Measurement of FRET
(represented by the ratio FYFP/FCFP) in single COS-1 cells transiently transfected
with YSmad1(SA)C and BMP receptors. Stimulation with BMP-4 showed no
response in FRET channel.
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2.7. FLIM data analysis and FRET calculations
Off-line FLIM data analysis used pixel-based fitting software (SPCImage
2.8, Becker & Hickl), able to import the binary data generated with the FLIM
module. The fluorescence usually fit best to and, thus, was always assumed to
follow a two-exponential decay which was used to calculate a weighted mean
lifetime per pixel for complete images. The fitting procedure also included an
adaptive offset correction and also convolution procedures to remove timing
jitter occurring from both the detectors and the electronics for accuracy (see
User's Manual for SPC-830 Software). ImageJ 1.37 (NIH) was used for
calculation of mean lifetime in cell areas.
Although both the CFP and YFP intensity signals were checked for appro-
priate levels (data not shown), we focused our attention to the CFP lifetime in the
purely expressed case of the CFP-fusion protein (τCFP=2.40±0.04 ns for CFP-
Smad1) or in the case of FRET (with co-transfection of the YFP fusion protein,
τCFP, FRET). The FRET efficiency from these data can be calculated from the
equation
FRET ¼ 1 sCFP;FRET
sCFP
 
The difference in calculated FRET before and after BMP-4 ligand addition
was multiplied by 100 and reported for pixel (and thus entire FRET images) and
also whole cell regions in % FRET change.
The calculation of relative CFP/YFP concentrations for the intermolecular
FRET-FLIM were performed by the same procedure listed above FRET
Microscopy section but with CFP (ICFP(430)) and YFP (IYFP, 430) photon
counting intensities from cellular regions with 430 nm excitation. The YFP
spillover or bleed-through correction into the CFP emission channel at 430 nm
excitation was 0.02. The YFP direct excitation crosstalk was determined to be
0.02. The CFP bleed-through or spillover crosstalk was determined to be 0.31.
The calculation of relative CFP/YFP ratios was also corrected by dividing by
the brightness of the individual, initial CFP (ICFP(430)) and YFP (IYFP, corr)
intensities:
ICFP(430)/(tCFP εCFP,430 φCFP) and IYFP, corr/(tYFP εYFP,430 φYFP) where tCFP
and tYFP are the optical transmissions for CFP and YFP in the respective CFP
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extinction coefficients of CFP (28,000 M−1 cm−1) and YFP (2000 M−1 cm−1) at
430 nm excitation and φCFP and φYFP are the fluorescence quantum yields of
CFP (0.36) and YFP (0.76) [45,46].
The level of CFP photobleaching was initially tested to be insignificant
according to the levels reported by Tramier et al. [54]. First the CFP
lifetimes were measured multiple times in CFP only transfected control cells
and showed no photobleaching under the experimental conditions and no
significant difference in lifetime. Second CSmad1 and YLSmad4 transfected
cells, 5 min before and immediately after BMP addition showed less than
10% photobleaching and less than 2% change in fluorescence lifetime
between the two successive images. Furthermore, we calculated the
“apparent photobleaching ratio” (as defined by Tramier et al. [54]) for the
CFP (ICFP(430)) in the CSmad1 and YLSmad4 transfected cells from the
intensity with images recorded at 15, 30, and 45 min after BMP addition
and used the t=0 min (i.e. immediately after BMP addition) as the initial
reference in every case.3. Results
3.1. Construction of a full-length Smad1 FRET biosensor
To better understand the kinetics of activation of Smad1, we
created a FRET sensor for Smad1 activation by fusing a cyan
fluorescent protein (CFP) to the C-terminus and a yellow fluo-
rescent protein (YFP) between the MH2 and the MH1 domains
with a linker. This FRETsensor was named Smad1YC (Fig. 1A).
As Smad1 is known to switch in its conformation upon
phosphorylation [26,47] we hypothesized that it might lead to
a change in the distance between the fluorophores upon
activation by the BMP receptors. The linker between the C-
terminus of Smad1 and CFP was inserted in order to avoid
impairing phosphorylation of Smad1 at its C-terminal SSXS
motif. Various linkers were tested, and a GSTSGSGK peptide
linker proved to be most effective (data not shown). However,
the Smad1 MH2 domain conformational change has also been
shown to occur with homo- and heterocomplex formation after
stimulation with a ligand [48]. First, we testedwhether the fusion
protein retained the phosphorylation properties of wild type
Smad1. To do this, COS-1 cells were transfected with the
Smad1YC expression plasmid for Western blot analysis. The
fusion protein was phosphorylated at a similar time as the
endogenous Smad1 in response to BMP-4 (Fig. 1B). We
conducted kinetic experiments by FRET microscopy in living
cells in order to test whether the Smad1YC fusion protein
functions as a biosensor reflecting Smad1 phosphorylation.
COS-1 cells were transiently transfected with plasmids encoding
Smad1YC and BMP receptors, and FRET in single cells (n=10)
between CFP and YFP was measured showing a signal decrease
in the YFP channel and an increase in the CFP channel (Fig. 2A
and C). Computerized analysis of the calculated FRET data wereFig. 5. BMP4-induced nuclear translocation of fluorescent Smad1 and Smad4 fusion
fused with a short linker sequence (L) to the N-terminus of human Smad4 to generate
time-lapse images of nuclear localization after BMP-4 and LMB addition (1, 30 an
CSmad1 or YLSmad4 and the BMP receptor. Cells were treated with BMP-4 (20 n
independent experiments. (D) The CSmad1/YLSmad4 time-lapse images of nuclear l
co-transfected with plasmids expressing CSmad1 and YLSmad4 and the BMP r
representative of at least three independent experiments.used to determine the kinetics of the FRET change (Fig. 2B). In
cells stimulated with BMP-4, the FRET signal decreased slowly
with an average time of 315±70 s but only after an initial delay
of 284±45 s with no FRET change (Fig. 2B).
To demonstrate that the FRET signal change reflects Smad1
phosphorylation, we mutated the Smad1 phosphorylation motif
(SSXS) by exchanging the three serines for alanines. The fusion
was named Smad1(SA)YC. COS-1 cells were transiently
transfected with plasmids encoding Smad1(SA)YC and BMP
receptors and analyzed by FRET. The Smad1(SA)YC did not
produce the same FRET change after BMP-4 addition as the
Smad1YC biosensor did (Fig. 2E). The signals in some cases
(n=3) rather showed an immediate slow decay with a time
constant of 800±180 s (Fig. 2D, right), but in most cases (n=5)
no FRET change or decay was observed at all (Fig. 2D, left).
The smaller and slower FRET decrease occurring in the
minority of cases of the non-phosphorylating mutant might be
due to interactions with other proteins (as indicated previously)
that could form a complex and thus slightly alter the con-
formational changes in the of non-phosphorylated mutated
Smad1YC constructions. In summary, the approximate 300-s
delay and 300-s decay are shown to be linked to the active,
phosphorylating Smad1YC biosensor.
3.2. Construction of a Smad1 MH2 domain-based FRET
biosensor
To analyze the role of the MH1 domain in more detail and
improve the understanding of the kinetics of Smad1 activation
by phosphorylation, we created a Smad1-MH2 biosensor
without the MH1 domain and linker. We also intended to create
a biosensor, with a faster response upon BMP-4 activation as
compared to the full Smad1 biosensor. To construct the
biosensor, the sequence of the human Smad1 MH2 domain
was flanked by sequences coding for YFP and CFP as shown in
Fig. 3A. This sensor was named YSmad1C. The same linker as
for Smad1YC was inserted between the C terminus of Smad1
and the CFP. COS-1 cells were transfected with plasmids
encoding YSmad1C and BMP receptors for Western blot
analysis of the phosphorylation properties. The Western blots
indicated that the YSmad1C showed a notably faster phosphor-
ylation rate than wild-type Smad1. The band reflecting the
phosphorylated fusion protein could be detected already without
BMP-4 stimulation, and the signal increased within the first
minute after BMP-4 addition (Fig. 3B). By contrast, phosphor-
ylation of the endogenous Smad1 protein (as a control in the
same cells) showed no significant phosphorylation within the
first 5 min after BMP-4 addition (Fig. 3B). Next, COS-1 cells
were transiently transfected with YSmad1C for FRET observa-proteins. (A) CFP was fused to the N-terminus of human Smad1, and YFP was
CSmad1 and YLSmad4, respectively. (B and C) The CSmad1 and the YLSmad4
d 60 min). COS-1 cells were transiently transfected with plasmids expressing
M) or LMB (2 nM). The experiments shown are representative of at least three
ocalization after LMB addition (1, 30 and 60 min). COS-1 cells were transiently
eceptor. Cells were treated with LMB (2 nM). The experiments shown are
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data were subjected to computerized analysis to determine the
kinetics of the FRET change. After stimulation of the cells withFig. 6. BMP4-induced functional activity of fluorescent Smad1 and Smad4
fusion proteins. (A) CSmad1 and YLSmad4 were expressed in COS-1 by
transient transfection. Cell extracts were harvested at different times after BMP-
4 stimulation and analyzed by Western blot with antibodies recognizing
phosphorylated Smad1 (αpSmad1), total Smad1, Smad4, or fluorescent proteins
(αFP). (B and C) MDA-MB468 cells lacking endogenous Smad4 were
transfected with the pSBELuciferase reporter plasmid and plasmids expressing
wild-type Smad4, YLSmad4 (for panel B), or wtSmad4 and CSmad1 (for panel
C). Cells were treated with BMP-4 for 8 h, and luciferase activity was measured.
The data are means and standard deviations of experiment performed in
triplicate. All experiments were repeated three times.BMP-4, a fast decrease with subsequent slow recovery of FRET
ratios was recorded with time constants of the decrease of 300
±40 s and of the slow increase of 600±140 s (Fig. 4B). We also
at times had observations of the same rate of FRET decrease
without any recovery (data not shown). To demonstrate that the
FRET signal changes reflected Smad1 phosphorylation we also
created the same YSmad1C fusion protein with an exchange of
the three distal serines to alanines. This fusion protein was
named YSmad1(SA)C. COS-1 cells were transiently transfected
with plasmids encoding YSmad1(SA)C and BMP receptors and
analyzed by FRET microscopy (n=6). As shown in Fig. 4D, the
serine-to-alanine mutations abolished the FRET change, indi-
cating that phosphorylation of the SSXS motif is required for the
FRET change.
In summary, the Western blot (Fig. 3B) and FRET
experiments (Fig. 4A) demonstrated that the YSmad1C sensor
lacking an MH1 domain was phosphorylated almost immedi-
ately after addition of BMP-4.
3.3. BMP4-induced nuclear translocation and transcriptional
activity of fluorescent Smad fusion proteins
To measure the interaction of Smad1 and Smad4 by FRET,
we constructed expression plasmids encoding fusion proteins
of human Smad1 with CFP (CSmad1) and Smad4 with YFP
and linker (YLSmad4) as depicted in Fig. 5A. We used a
linker between YFP and Smad4 to preserve the functional
activity of Smad4. A linker was not necessary for the CSmad1
fusion protein. Nuclear translocation of CSmad1 and YLS-
mad4 upon BMP-4 response would be an indicator of
physiologically normal behavior, as has been shown for
endogenous Smads [37]. To test this, we transfected COS-1 or
HEK 293 cells with the fluorescent Smad fusion expression
plasmids and analyzed the behavior of the fusion proteins in
the absence or presence of BMP-4 (Fig. 5B and C). To ensure
that the CFP/YFPSmads perform nucleocytoplasmic shuttling
in the absence of BMP-4 stimulation, cells were pretreated
with leptomycin B (LMB), which inhibits the nuclear export
by CRM1/exportin-1. CRM1 has previously been identified as
the nuclear transporter for NES-dependent export [49].
CSmad1 and YLSmad4 were predominantly cytoplasmic in
untreated cells and predominantly nuclear in cells treated with
LMB (Fig. 5B and C). Similarly, the fusion proteins accumulated
in the nucleus after 60 min of induction with BMP-4 (Fig. 5B
and C).
To test whether co-expression of the two Smad fusion
proteins, CSmad1 and YL1Smad4, impairs nuclear transloca-
tion, COS-1 cells were co-transfected with both CSmad1 and
YLSmad4 expression plasmids to observe in parallel nuclear
translocation of each fusion protein over time upon BMP-4 or
LMB addition. With confocal microscopy, we clearly observed
that co-expression does not prevent nuclear translocation of both
fusion proteins upon LMB addition (Fig. 5D). The parallel
observation of nuclear translocation of each fusion protein over
time upon BMP-4 addition was more difficult. Previously
published results of others indicated that nuclear translocation in
complexes is less favored in comparison to the translocation of
Fig. 7. Intermolecular FRET kinetics of CSmad1 and YSmad4 in single (A) COS-1 and (B) HeLa, (C) MDA-MB-468 cells. Cells were co-transfected with plasmids
encoding the Smad fusion proteins and the BMP receptor. Stimulation with BMP-4 caused very little response in the FRETchannel for a dormant period of about 300 s,
after which a FRET increase occurred with a time constant of about 600 s with a corresponding increase in the YFP and a decrease in the CFP channel. (D) MDA-
MB468 cell transiently expressing BMP receptors and YLSmad4 and CSmad1 fusion proteins were analyzed by a technique called Donor Dequenching after Acceptor
Photobleaching. Emission Intensities of YFP (535 nm, yellow) and CFP (480 nm, cyan) were recorded before and after the acceptor fluorophore (YFP) was completely
photobleached with 500 nm excitation light. (In all figures, the CFP:YFP concentration ratio was reported. See Materials and methods and also Results for the
calculation and interpretation of the ratios.)
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Smads have a lower mobility and apparently lower nuclear
translocation probabilities spatially in heterocomplex. Nonethe-
less, nuclear translocation of the fusion proteins upon BMP
addition, was observed by means of confocal fluorescence
lifetime imaging (FLIM), a technique which can determine
FRET efficiency by changes in the fluorescence lifetime of the
donor in the presence of the acceptor on a pixel-by-pixel basis
for time-lapsed images on the minute time-scale (see Materials
and methods). We could indeed observe nuclear translocation of
CSmad1/YLSmad4 upon BMP-4 addition with FLIM and
describe it in the next section.
The transcriptional activity of CSmad1 and YLSmad4
was subsequently tested in established assays to ensure that
they retained the activity of wild-type Smads. COS-1 cells
were transfected with these expression plasmids for Western
blot analysis. The Western blots indicated that CSmad1 was
phosphorylated efficiently in response to BMP-4, as was
endogenous Smad1 (Fig. 6A). We also tested whether
complexes of Smad1 and Smad4 fusion proteins were
transcriptionally active using a luciferase reporter assay
similar to the one previously used by Nicolas et al. [40]. To
do this, the Smad fusion proteins were expressed in MDA-
MB468 cells which lack endogenous Smad4, but contain R-
Smads. The results of the luciferase assays were difficult to
obtain without long periods of starvation (see Materials and
methods) due to over-expression of endogenous R-Smads
mixed with normal cell signaling activities creating unfavor-
able basal activities. The starvation apparently reduces the
endogenous Smad1 levels so that co-transfection of both
Smad1 and Smad4 was necessary to observe the difference
between the active and non-active cells. A Smad1/Smad4-
dependent luciferase reporter plasmid, pSBELuciferase, con-
taining the Smad binding element [50] was transiently
transfected together with the CSmad1 (Fig. 6B) or YLSmad4
(Fig. 6C) expression plasmid. As shown in Fig. 6B, luciferase
expression was enhanced by co-transfecting wtSmad4 with
CSmad1. YLSmad4 co-transfected with wtSmad1 also in-
creased the luciferase activity (Fig. 6C).
From the data presented in this part we concluded that
CSmad1 and YLSmad4 retain the normal function as a tran-
scription factor.Fig. 8. Observation of intermolecular FRET kinetics of CSmad1 and YLSmad4 in
analysis of CSmad1 in 17 HeLa cells co-transfected with CSmad1 and YLSmad4 (left
donor mean lifetime decreases from 2.27±0.03 ns to 1.87±0.03 ns for the 17 HeLa ce
nuclear translocation of FRETshown in detail in the panels below. (A, bottom panels)
transmission, FLIM, FLIM plus transmission and transmission of the nuclear transl
45 min after BMP-4 addition (scale bar, 10 μm). (B) Graph shows histogram and dis
with CSmad1 and YLSmad4 from panel A.ΔFRETefficiencies were calculated at 15
the FRETat t=0 min immediately after BMP addition. Both column graphs were fitted
t=15 min and 11±1% at t=45 min. (C) FRET efficiency change of 17 HeLa cells t
experiment were taken for calculation of FRET efficiency. The FRET efficiency befo
column indicates the change in FRET efficiency after 15 min, the gray columns after
average corrected CFP/YFP ratio and average apparent CFP photobleaching were
insignificant CFP photobleaching and no reorganisation of CFP signal inside of the c
cells with significant CFP photobleaching and reorganisation of CFP signal inside o
without reorganisation of CFP signal within the cell. (See Materials and methods fo
values.)3.4. Kinetic studies of Smad1/Smad4 fusion proteins complex
formation
We wanted to use the Smad fusion proteins to measure the
complex formation rate between CSmad1 and YLSmad4 by
FRET. COS-1 (n=3), HeLa (n=3) and MDA-MB468 (n=3)
cells were transiently transfected with plasmid constructs
expressing CSmad1, YLSmad4, and BMP receptors. Then we
observed the kinetics of heteromeric complex formation of these
fusion proteins before and after stimulation with BMP-4. The
experiments in Fig. 7A and B demonstrated that FRET occurred
between these constructs in COS-1 and HeLa cell after addition
of BMP-4 with corresponding increases in the YFP channel and
decreases in the CFP channel. Computer-assisted analysis of the
FRET data revealed an increase of the FRET signal in the cells
with an average time constant of 517±160 s, but only after a 260
±48 s delay with no FRET change (Fig. 7A and B). A two times
higher amplitude of FRET increase was observed in MDA-
MB468 breast cancer cells. This could be explained by the
absence of the endogenous Smad4 that likely serves as a
competitor of the Smad4 fusion protein (Fig. 7C). We also
performed another control in which we reliably determined
FRET in the MDA-MB468 cell line (n=3) (20 min after BMP-4
addition) by acceptor photobleaching. We selectively photo-
bleached the acceptor and, as expected, this maneuver
significantly decreased the fluorescence of YFP accompanied
by successive increase in the fluorescence of CFP by 15% (Fig.
7D). The donor to acceptor ratios ranges measured for all of the
CSmad1/YLSmad4 intermolecular FRET cells from Fig. 7 (and
further measured cells for statistics with data not shown) were
between 0.7 and 2.1. Between these values, no major trends of
FRET change and CFP/YFP ratio were observed. Although a
few trials were attempted well above and well below these CFP/
YFP ratio ranges, a stable FRET was never observed. These
observations are in accordance with the predicted donor to
acceptor concentration range of 0.1 to 10 byBerney et al. [51] for
a stable, detectable FRET to occur.
As an additional method for proving intermolecular FRET
we used fluorescence lifetime imaging (FLIM). We transiently
co-transfected HeLa cells with plasmid constructs expressing
CSmad1, YLSmad4, and BMP receptors. We observed the
kinetics of FRET of these fusion proteins before and afterHeLa cells with FLIM. (A, upper panels) Fluorescence lifetime image (FLIM)
) immediately after (t=0 min) and (right) t=45 min after addition of BMP-4. The
lls 45 min after BMP-4 addition (scale bar, 50 μm). A cell is encircled as it shows
shows a zoomed pure CFP, pure CFP plus transmission, pure YFP, pure YFP plus
ocation FRET example from the upper panels immediately after (t=0 min) and
tribution of FRET dynamics from the pixels of the 17 HeLa cells, co-transfected
min (dashed lines) and at 45 min (solid lines) after BMP addition subtracted from
with single Gaussian curves and reveal a change in FRETefficiency of 6±1% at
ransfected with CSmad1 and YLSmad4. TCSPC data from sample and control
re BMP addition serves as reference to show the dynamics of FRET. The white
30 min and the black columns after 45 min of BMP-4 addition. For each cell the
reported. The cells are represented in four categories: 1—shows cells with
ell, 2—displays cells like category 1 but with CFP reorganization, 3—indicates
f the cell and 4—demonstrates cells with significant CFP photobleaching and
r their determinations and Results for a discussion and determination of these
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measured every 15 min.
Analysis of the CFP lifetime of the 17 HeLa cells in Fig. 8A
(upper panels) revealed a significant decrease in fitted and
averaged decay time constants from 2.27±0.06 ns before
addition to 1.87±0.03 ns 45 min after addition of BMP-4.
Shorter fluorescence lifetimes in comparison to the pure CFP
lifetime (in this case of singly expressed CSmad1 in HeLa cells)
are due to the interaction with the acceptor molecule (YLSmad4)
causing the FRET [45,52,53]. Furthermore, the ratio of the CFP
(FRET) lifetime to the pure CFP lifetime can be used to calculate
the FRET efficiency (see Materials and methods). Before BMP
addition of the co-transfected CSmad1/YLSmad4 HeLa cells
(n=17), the CFP lifetime indicated a base-line FRET efficiency
of 5±2% in contrast to 45 min after addition revealing a FRET
efficiency of 22±2% giving rise to a total FRET change
(ΔFRET) of 17±4%.
The ΔFRET was calculated on a pixel-by-pixel basis for all
of the 17 cells showing a normal distribution (see Fig. 8B for
15 min and 45 min after BMP addition) to verify mean and
standard error distribution of the FRET change (6±1% for
15 min and 11±1% for 45 min after BMP addition). The slight
differences in FRET change calculation here (in comparison to
the 17% calculated above) are almost entirely due to pixel shifts
in time during image acquisition mostly due to the slow mi-
gration of the cells.
TheΔFRETwas also determined for the 17 individual cells at
15, 30, and 45min after BMP addition to show the dynamics and
statistics contributing to this FRET (Fig. 8C). A majority of cells
(11 of 17 and 12 of 17) show a significant ΔFRET increase of
N6% in 30 and 45 min after addition, respectively, with nearly
half (7 of 17) showing a N6% ΔFRET in 15 min after addition.
The range of CFP/ YFP ratios where ΔFRET occurred was
found to be between 0.3 and 3.1 agreeing to the acceptable range
as reported by Berney et al. However, due to the possibility of
photobleaching (discussed below), and removal of data from
photobleaching, the dynamic range would be reduced to 0.7 to
3.1, overlapping the values reported above.
Photobleaching of CFP has also been shown to affect fluo-
rescence lifetime measurements and, thus, could cause a falsely
reported FRET or ΔFRET [54]. Care was taken to use ex-
perimental conditions that did not allow photobleaching (see
Materials and methods). However, upon application of the
“apparent photobleaching ratio” (as defined by Tramier et al.
[54]) for the CFP (see Materials and methods for calculation and
Fig. 8C for individual cell values), 7 cells showed a significant
“apparent photobleaching” (N0.3) and two cells showed a slight
“apparent photobleaching” (b0.3 but N0.1) causing greater than
20% shorter CFP fluorescence lifetimes in the significant case
and less than 10% shorter lifetimes in the slight case. Because the
possibility exists that further CFP fluorescence intensity de-
creases, indicated by a lower “apparent photobleaching” value,
could occur to either reorganization (by nuclear localization or
cell shifting) or to photobleaching, we have further categorized
all of the form from CFP for measurements into four possible
cases: no photobleaching and no reorganization, no photo-
bleaching and reorganization, photobleaching and reorganiza-tion, and photobleaching and no reorganization. The ΔFRET
remains to be highly significant after rejection for any possibility
of photobleaching with 5 of the 8 cells N0.04. The ΔFRET
improves even further in dynamics and statistics if the
reorganization of CFP rules out the photobleaching rejection
with 12 of 15 cells N0.04 and 9 of 15 cells N0.06.
As mentioned above, we show in Fig. 8A (upper panels)
FLIM images of CSmad1 before and after BMP-4 addition that
have significantly decreasing donor (CFP) lifetimes in the
majority of cases in the cytosol (12 of 17 cells) and that also
show in some cases the FRET change slowly traveling in to the
nucleus of HeLa cells (4 of 17 cells). Only one cell showed a
comparatively clear CSmad1 and YLSmad4 nuclear transloca-
tion to complement the nuclear translocating FRET (Fig. 8A
(encircled cell in upper panels) and (bottom panels)).
4. Discussion
In this study we report the development of fluorescent
biosensors for direct visualization of Smad signaling. With
these Smad biosensors we have investigated the kinetics of
Smad1 activation which is defined by phosphorylation-induced
concerted structural changes of the MH2 domain. In addition,
the kinetics of the Smad1/Smad4 complex formation was
analyzed by FRET using CFP and YFP fusions of Smad1 and
Smad4, respectively. We have also demonstrated that these
Smad fusion proteins closely mimic the behavior of endogenous
Smad1 and Smad4 in terms of their activation and their for-
mation of active Smad transcription factor complexes on Smad-
responsive elements.
The kinetics of activation of Smad1 is a paradox in that it
diffuses quickly through the cell but phosphorylates slowly.
Using FRET we first addressed the question, what is the rate-
limiting step of the BMP signaling cascade. BMP-4 signals via
two types of receptors (BRI and BRII) that are expressed at the
cell surface as homomeric or heteromeric complexes. The
ligand, in this case BMP-4, has two options for binding to the
receptors. It can bind to the high-affinity receptor BRI and then
recruit BRII into a hetero-oligomeric complex. This process
leads to activation of the Smad independent p38-MAPK
pathway. The other alternative is to bind simultaneously to the
preformed hetero-oligomeric complexes. These complexes then
activate the Smad signaling pathway [55]. In previous pub-
lications [6,55,56] and own unpublished data, a high concen-
tration of preformed complexes of BMP receptors which signal
towards the Smad pathway was observed on the cell surface.
Thus, we made the presumption that upon BMP-4 binding, there
should be instantaneously activated receptor available to
phosphorylate Smad1. Therefore, the BMP receptor activation
should not be a limiting step of the Smad signaling pathway.
Recently, the cytosolic diffusion constants were reported for
Smad2 before activation. The diffusion was so fast that there
should nearly always be Smad2 available for phosphorylation
[39]. A similarly fast diffusion can be assumed also for Smad1.
However, the kinetics of Smad2 phosphorylation and Smads
deduced from Western blot analyses showed that the phosphor-
ylated Smads were observed after 10–15 min incubation with
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phosphorylation the rate-limiting step of BMP-4 signaling? To
answer this question we have developed novel fluorescent
biosensors of Smad1 that reflect the kinetics of Smad1
phosphorylation. One sensor was created as a fusion of the
full-length Smad1 with YFP and CFP (Smad1YC). By Western
blot we demonstrated that this biosensor had phosphorylation
kinetics similar to wild-type Smad1. Upon activation by
phosphorylation, Smad1 undergoes a conformational switch
[26,47,48] that should correspond with a FRET change with our
engineered Smad biosensor. However, several processes could
occur that could slow the process such as diffusion driven
processes or protein binding. In any case, the changes in the
FRET level should be an indicator of the progression for
cytosolic Smads to become phosphorylated. We suggest the
following possibilities for the non-instantaneous FRET re-
sponse: the endocytosis of the BMP receptors [57], binding
before phosphorylation with other proteins, RSmad stays bound
to receptor after phosphorylation and not allowing more to be
bound or that the event is complex formation. The bottom line is
that all these processes can cause retardation in Smad signaling.
After phosphorylation the Smad1 MH2 domain undergoes a
conformation change and interacts with the C-terminal tails of
other Smad1 MH2 domains forming a homotrimer [48]. Thus, it
is possible that both, phosphorylation and homotrimerization
contribute to the FRET changes.
In the FRET experiments, high initial FRET ratio levels were
observed. After BMP-4 stimulation of COS-1 cells, FRET
signals from Smad1YC displayed an initial “non-response”
period of 315±70 s with a subsequent slow decrease with an
average time constant of 284±45 s indicating there are dynamic
events occurring up to the phosphorylation process. In C2C12
and HEK 293 cells, a slightly shorter “non-response” period of
100–300 s followed by a slow signal decrease with an average
time 300 s was observed (data not shown). This indicates that
the kinetics of Smad1 activation may to some extent be cell
type-specific leading to the hypothesis that the delay originates
from the endocytosis rate of the BMP receptors on the plasma
membrane as the corresponding delays reflect cell-type in-
ternalization rates [58]. For the period of 100–300 s after BMP-
4 addition when we could not observe any change in FRET, we
suggest that a slow, gated type of diffusion-controlled reaction
is naturally occurring in the cells. Our interpretation of the
“dead” response time after stimulation with BMP-4 is that it is
an important kinetic factor of the Smad signaling process and
perhaps even a major bottleneck to the kinetics of Smad
signaling. What could cause the delayed response upon BMP-4
stimulation? Previous studies have shown that the MH1 domain
of Smad1 is responsible for binding not only to specific DNA
sequences, but also to cytoskeletal proteins [9]. Moreover, the
MH1 domain has a regulatory role in inhibition of the Smad
molecule in the cytoplasm prior to activation. This inhibition is
mediated through the binding of the MH1 domain to an
opposing MH2 domain of R-Smad, and Smad phosphorylation
upon activation is thought to relieve it [5,7,9,59,60]. However,
there has been no direct evidence that the MH1 domain could be
responsible for regulation of Smad1 phosphorylation. It has alsobeen shown that R-Smads are anchored at the cell membrane by
interacting with various cytoplasmic proteins, including SARA
which recruits and stabilizes the monomeric form of Smad2/3.
This protein could also be responsible for the delay in Smad1
activation [25]. Smad1 was also observed to interact with the
cytoplasmic domain of CD44, which anchors Smad1 at the
plasma membrane [61] and could have a role in delaying Smad1
activation. Furthermore, the full number of Smad interacting
proteins still remains to be determined [9,62]. All these factors
could cause the delayed FRET response after BMP-4 stimula-
tion. In fact, the regulatory process of R-Smad activation could
be one of the rate limiting steps of the BMP receptor signaling
pathway in general.
We addressed the questionwhether theMH1 domain could be
responsible for the delay in Smad1 phosphorylation by
developing a sensor based solely on the MH2 domain. The
MH2-only Smad1 biosensor lacking the MH1 domain
(YSmad1C) demonstrated how the MH1 domain influences
the kinetics of R-Smad activation. Both, FRET measurements
andWestern blot analysis clearly showed that the YSmad1Cwas
activated without the delay that wild-type Smad1 and the
Smad1YC displayed. After stimulation with BMP-4 we
observed that the FRET ratio quickly dropped (without the
delay observed with the full sensor) with a time constant of 300
±40 s, suggesting that this reflects the dynamics without the
delay observed in the full Smad biosensor up to the
conformational changes in MH2 domain. A second phase of
the FRET change was a slow recovery with a time constant of
600±140 s but was not always observed. These FRET ex-
periments and those with the mutated sensor, YSmad1(SA)C,
indicated that the FRET decrease reflected phosphorylation of
the MH1-deficient Smad1, which apparently starts immediately
without delay after BMP-4 addition. The data also demonstrate
the important role of MH1 domain in regulating Smad1
phosphorylation. However, homotrimerization of the MH2
domain of Smad1 upon BMP stimulation could also contribute
in the FRET changes as for Smad1YC biosensor. Thus,
YSmad1C FRET signals can be robustly and more quickly
detected than with the full sensor and potentially many times
faster than withWestern blot or luciferase assays. The usefulness
of the YSmad1C biosensor was also further shown in that it is
reversible in a low number of cases (∼10%) tested by first
observing the FRET decrease upon BMP-4 addition, removal of
the BMP-4, waiting for a long period (N30 min) for recovery,
and observation of the FRET decrease again in the same cell
upon a second addition of BMP-4 (data not shown).
We have gone on to use FRET experiments to study the
kinetics of Smad1/Smad4 complex formation inmore detail. The
results demonstrated that CSmad1 and YLSmad4 form a
heteromeric complex in BMP-4 stimulated cells after a delay
of 260±48 s. The time constant fit from the FRET ratio increase
after stimulation with BMP-4 is on the order of 517±160 s and
indicates how slow the complex formation process is between
CSmad1 and YLSmad4. With the addition of FLIM, the
statistics of positive recordings of the CSmad1/YLSmad4
complexation upon BMP addition in individual cells is quite
high (70%). We also show by confocal microscopy and FLIM
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the nucleus to further add to the usefulness of the biosensors.
Recent studies have shown an important role of TGF-β
signaling in the regulation of cancer [63,64]. For example,
specific mutations and deletions of the genes for R-Smad
proteins occur in different human carcinomas [65]. Therefore,
we believe that the fluorescent Smad biosensors could be used as
a new fast tool for the screening of drugs against certain cancers.
The work presented here directly demonstrates the kinetics of
Smad1 activation upon phosphorylation and heteromeric
complex formation in real time and in living cells. With the
advent of the Smad biosensors, the inception of Smad activation
and complex formation can be observed in single living cells. In
the future, this method could be used to build a complete kinetic
model of BMP signaling that can help to calculate the behavior
of the processes in the cell under different physiological
conditions. Our results suggest that Smad1 phosphorylation is
a rate-limiting step of the BMP signaling pathway. We have also
created a sensor, the YSmad1C, with the MH1 domain deleted
that has optimized the speed by removing the rate-limiting delay
and the dynamic range of the FRET response by closer proximity
of the fluorophores. Such physiological detectors allow us to
further study the kinetics of BMP signaling pathways upon
addition of different ligands. Furthermore, these sensors could
give new insights into the BMP receptor–Smad1/4 signaling
process and potentially provide a powerful tool for studying
Smads, their physiological role and spatio-temporal regulation
of Smad-dependent processes.
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